Jane Street’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Jane Street’s Portfolio NVIV Stock Details NVIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,872	Closed	-$21K	–	11541
2021 Q4	$21K	Buy	+1,872	New	+$26.9K	﹤0.01%	9788
2021 Q2	–	Sell	-929	Closed	-$23K	–	10880
2021 Q1	$23K	Buy	+929	New	+$27.8K	﹤0.01%	8965
2015 Q3	–	Sell	-1	Closed	-$277K	–	4452
2015 Q2	$277K	Buy	+1	New	+$264K	﹤0.01%	2901

Other funds holding NVIV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ICM

IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

Jane Street's NVIV Position: Q1 2022 in Review

Jane Street sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q1 2022, closing a stake of 1,872 shares — an estimated $21K sold.

Jane Street first reported a position in NVIV in Q2 2015 and held it in 3 quarters. The position peaked at $277K in Q2 2015. 16 funds tracked by Wall St. Rank hold NVIV as of Q1 2022.

Jane Street reported no remaining InVivo Therapeutics Holdings Corp position as of Q1 2022 after selling out during the quarter.
Jane Street sold 1,872 InVivo Therapeutics Holdings Corp shares in Q1 2022, an estimated $21K.
Jane Street first reported a position in InVivo Therapeutics Holdings Corp in Q2 2015 and held it in 3 quarters.
Jane Street's InVivo Therapeutics Holdings Corp position peaked at $277K in Q2 2015.
16 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q1 2022.

Based on Jane Street's 13F filing for Q1 2022, filed 17 May 2022.